Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127445947> ?p ?o ?g. }
- W2127445947 endingPage "2004" @default.
- W2127445947 startingPage "1995" @default.
- W2127445947 abstract "We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs).A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS).The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%).Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity." @default.
- W2127445947 created "2016-06-24" @default.
- W2127445947 creator A5001037498 @default.
- W2127445947 creator A5005981256 @default.
- W2127445947 creator A5010891460 @default.
- W2127445947 creator A5012574547 @default.
- W2127445947 creator A5014180821 @default.
- W2127445947 creator A5019545869 @default.
- W2127445947 creator A5020314370 @default.
- W2127445947 creator A5024275078 @default.
- W2127445947 creator A5025093710 @default.
- W2127445947 creator A5029952866 @default.
- W2127445947 creator A5031998230 @default.
- W2127445947 creator A5039810007 @default.
- W2127445947 creator A5057387932 @default.
- W2127445947 creator A5059965175 @default.
- W2127445947 creator A5061560391 @default.
- W2127445947 creator A5061914021 @default.
- W2127445947 creator A5071164705 @default.
- W2127445947 creator A5071553983 @default.
- W2127445947 creator A5077968783 @default.
- W2127445947 creator A5085981984 @default.
- W2127445947 date "2009-11-10" @default.
- W2127445947 modified "2023-10-08" @default.
- W2127445947 title "Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma" @default.
- W2127445947 cites W1858161324 @default.
- W2127445947 cites W1859686868 @default.
- W2127445947 cites W1868719232 @default.
- W2127445947 cites W1911329365 @default.
- W2127445947 cites W1959628099 @default.
- W2127445947 cites W1984246155 @default.
- W2127445947 cites W1988698591 @default.
- W2127445947 cites W1993119221 @default.
- W2127445947 cites W2001355942 @default.
- W2127445947 cites W2018101957 @default.
- W2127445947 cites W2022290094 @default.
- W2127445947 cites W2033480740 @default.
- W2127445947 cites W2034407706 @default.
- W2127445947 cites W2034457052 @default.
- W2127445947 cites W2034548257 @default.
- W2127445947 cites W2054101759 @default.
- W2127445947 cites W2058707578 @default.
- W2127445947 cites W2061288640 @default.
- W2127445947 cites W2072483737 @default.
- W2127445947 cites W2072524389 @default.
- W2127445947 cites W2086632345 @default.
- W2127445947 cites W2096287682 @default.
- W2127445947 cites W2098588666 @default.
- W2127445947 cites W2098983401 @default.
- W2127445947 cites W2108151310 @default.
- W2127445947 cites W2118311655 @default.
- W2127445947 cites W2124512686 @default.
- W2127445947 cites W2127745545 @default.
- W2127445947 cites W2131397638 @default.
- W2127445947 cites W2132697290 @default.
- W2127445947 cites W2137586969 @default.
- W2127445947 cites W2137832651 @default.
- W2127445947 cites W2153624174 @default.
- W2127445947 cites W2168820857 @default.
- W2127445947 cites W2188149910 @default.
- W2127445947 cites W4253705647 @default.
- W2127445947 doi "https://doi.org/10.1038/sj.bjc.6605411" @default.
- W2127445947 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2795431" @default.
- W2127445947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19904263" @default.
- W2127445947 hasPublicationYear "2009" @default.
- W2127445947 type Work @default.
- W2127445947 sameAs 2127445947 @default.
- W2127445947 citedByCount "113" @default.
- W2127445947 countsByYear W21274459472012 @default.
- W2127445947 countsByYear W21274459472013 @default.
- W2127445947 countsByYear W21274459472014 @default.
- W2127445947 countsByYear W21274459472015 @default.
- W2127445947 countsByYear W21274459472016 @default.
- W2127445947 countsByYear W21274459472017 @default.
- W2127445947 countsByYear W21274459472019 @default.
- W2127445947 countsByYear W21274459472020 @default.
- W2127445947 countsByYear W21274459472021 @default.
- W2127445947 countsByYear W21274459472022 @default.
- W2127445947 countsByYear W21274459472023 @default.
- W2127445947 crossrefType "journal-article" @default.
- W2127445947 hasAuthorship W2127445947A5001037498 @default.
- W2127445947 hasAuthorship W2127445947A5005981256 @default.
- W2127445947 hasAuthorship W2127445947A5010891460 @default.
- W2127445947 hasAuthorship W2127445947A5012574547 @default.
- W2127445947 hasAuthorship W2127445947A5014180821 @default.
- W2127445947 hasAuthorship W2127445947A5019545869 @default.
- W2127445947 hasAuthorship W2127445947A5020314370 @default.
- W2127445947 hasAuthorship W2127445947A5024275078 @default.
- W2127445947 hasAuthorship W2127445947A5025093710 @default.
- W2127445947 hasAuthorship W2127445947A5029952866 @default.
- W2127445947 hasAuthorship W2127445947A5031998230 @default.
- W2127445947 hasAuthorship W2127445947A5039810007 @default.
- W2127445947 hasAuthorship W2127445947A5057387932 @default.
- W2127445947 hasAuthorship W2127445947A5059965175 @default.
- W2127445947 hasAuthorship W2127445947A5061560391 @default.
- W2127445947 hasAuthorship W2127445947A5061914021 @default.
- W2127445947 hasAuthorship W2127445947A5071164705 @default.
- W2127445947 hasAuthorship W2127445947A5071553983 @default.